BSE
NSE

NSE Prices delayed by 15 minutes ! Prices as on Sep 10, 2026 - 3:59PM

ABB India 7329 [ -0.98% ]
ACC 1254.3 [ -0.27% ]
Ambuja Cements 395.6 [ -0.35% ]
Asian Paints 2498.1 [ 0.37% ]
Axis Bank 1246 [ 0.61% ]
Bajaj Auto 11768 [ -0.19% ]
Bank of Baroda 237.62 [ 1.50% ]
Bharti Airtel 1839 [ 1.34% ]
Bharat Heavy 429.5 [ -0.97% ]
Bharat Petroleum 303 [ -0.18% ]
Britannia Industries 5009 [ -1.59% ]
Cipla 1373.3 [ 0.75% ]
Coal India 432 [ 0.23% ]
Colgate Palm 1808.5 [ 0.47% ]
Dabur India 376.45 [ 1.32% ]
DLF 655.85 [ 0.11% ]
Dr. Reddy's Lab. 1143 [ -0.17% ]
GAIL (India) 174.49 [ -0.23% ]
Grasim Industries 3319 [ 0.58% ]
HCL Technologies 1207 [ -1.85% ]
HDFC Bank 693.8 [ 0.98% ]
Hero MotoCorp 5280 [ 1.19% ]
Hindustan Unilever 1942.3 [ -0.14% ]
Hindalco Industries 1014 [ -1.26% ]
ICICI Bank 1384.5 [ -0.33% ]
Indian Hotels Co. 715.75 [ -0.97% ]
IndusInd Bank 993.3 [ -1.07% ]
Infosys 1036.5 [ 0.14% ]
ITC 259.3 [ -0.58% ]
Jindal Steel 1137 [ -0.83% ]
Kotak Mahindra Bank 416.55 [ 0.62% ]
L&T 3955 [ 0.83% ]
Lupin 2077.8 [ -1.06% ]
Mahi. & Mahi 3123.8 [ -0.83% ]
Maruti Suzuki India 12590 [ -0.22% ]
MTNL 25.1 [ -0.44% ]
Nestle India 1386.2 [ -0.49% ]
NIIT 94.09 [ -0.95% ]
NMDC 84.6 [ -1.40% ]
NTPC 335 [ 0.15% ]
ONGC 237.27 [ 1.39% ]
Punj. NationlBak 116.85 [ 1.07% ]
Power Grid Corpn. 271.75 [ 2.22% ]
Reliance Industries 1274 [ -0.39% ]
SBI 1009.7 [ 0.92% ]
Vedanta 269.05 [ -1.27% ]
Shipping Corpn. 285.2 [ -0.75% ]
Sun Pharmaceutical 1861 [ -0.21% ]
Tata Chemicals 610.55 [ 1.24% ]
Tata Consumer 999.6 [ -0.14% ]
Tata Motors Passenge 300.5 [ -0.83% ]
Tata Steel 186.78 [ -1.04% ]
Tata Power Co. 367 [ -0.81% ]
Tata Consult. Serv. 2204.1 [ -0.18% ]
Tech Mahindra 1525.8 [ 1.18% ]
UltraTech Cement 10979 [ 0.72% ]
United Spirits 1400 [ -0.37% ]
Wipro 166.3 [ -0.42% ]
Zee Entertainment 80.95 [ -5.55% ]

Partner with US

Open an Demat Account

Portfolio Tracker

News Details
Home

News Details

04/09/2026 10:21

Back

Cipla join hands with Qilu Pharmaceutical to launch Keytruda biosimilar in US

Cipla Ltd on Thursday announced that its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical to license and supply a biosimilar of the cancer drug Keytruda in the United States.

The product, QL2107, is a biosimilar of pembrolizumab (Keytruda) and is aimed at expanding access to advanced cancer treatments while helping reduce treatment costs, Cipla said in a regulatory filing.

Under the partnership, Qilu will oversee the product's development, regulatory registration and supply, while Cipla will use its commercial presence in the US to market the asset.